Table A16:
Number of Patients Considered in Budget Impact Analysis, Reference Case
| Scenario | Year | Patients per Year,a,b Total (Alivec), n | Total Patients, n | |||||
|---|---|---|---|---|---|---|---|---|
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | ||||
| Current | TAVI | 2018/19 | 0 | — | — | — | — | 0 |
| scenario | 2019/20 | 0 | 0 | — | — | — | 0 | |
| 2020/21 | 0 | 0 | 0 | — | — | 0 | ||
| 2021/22 | 0 | 0 | 0 | 0 | — | 0 | ||
| 2022/23 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| SAVR | 2018/19 | 266 (266) | — | — | — | — | 266 (266) | |
| 2019/20 | 272 (272) | 266 (231) | — | — | — | 538 (503) | ||
| 2020/21 | 276 (276) | 272 (236) | 266 (215) | — | — | 814 (727) | ||
| 2021/22 | 281 (281) | 276 (240) | 272 (220) | 266 (200) | 1,095 (941) | |||
| 2022/23 | 285 (285) | 281 (244) | 276 (223) | 272 (205) | 266 (186) | 1,380 (1,43) | ||
| New scenario | TAVI | 2018/19 | 200 (200) | — | — | — | — | 200 (200) |
| 2019/20 | 218 (218) | 200 (179) | — | — | — | 417 (397) | ||
| 2020/21 | 235 (235) | 218 (195) | 200 (169) | — | — | 652 (599) | ||
| 2021/22 | 253 (253) | 235 (210) | 218 (185) | 200 (158) | — | 905 (806) | ||
| 2022/23 | 271 (271) | 253 (227) | 235 (199) | 218 (173) | 200 (147) | 1,175 (1,017) | ||
| SAVR | 2018/19 | 67 (67) | — | — | — | — | 67 (67) | |
| 2019/20 | 54 (54) | 67 (58) | — | — | — | 121 (112) | ||
| 2020/21 | 41 (41) | 54 (47) | 67 (54) | — | — | 162 (142) | ||
| 2021/22 | 28 (28) | 41 (36) | 54 (44) | 67 (50) | — | 190 (158) | ||
| 2022/23 | 14 (14) | 28 (24) | 41 (33) | 54 (41) | 67 (46) | 205 (159) | ||
Abbreviations: SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation.
a
Numbers may appear inexact due to rounding.
b
Year 1 represents all new patients, years 2 to 5 represent patients who have received TAVI or SAVR in a previous year.